Alemtuzumab Plus Peripheral Stem Cell Transplantation in Treating Patients With Chronic Lymphocytic Leukemia

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Diagnosis of chronic lymphocytic leukemia (CLL) that meets the following criteria at any point prior to study entry:
• •* Peripheral blood absolute blood count greater than 5,000/mm\^3
• •* Lymphocytosis must comprise small to moderate size lymphocytes with no more than 55% prolymphocytes, atypical lymphocytes, or lymphoblasts morphologically
• •* Phenotypically characterized B-cell CLL
• •* Splenomegaly, hepatomegaly, or lymphadenopathy not required for CLL diagnosis
• •Must have bone marrow biopsy within 4 weeks of study entry showing cellularity of at least 25% of intratrabecular space and lymphocytes accounting for no more than 30% of nucleated cells
• •PATIENT CHARACTERISTICS:
• •Age:
• •18 to 65
• •Performance status:
• •ECOG 0-1
• •Life expectancy:
• •Not specified
• •Hematopoietic:
• •See Disease Characteristics
• •Absolute neutrophil count at least 1,000/mm\^3
• •Hemoglobin at least 11 g/dL
• •Platelet count at least 100,000/mm\^3
• •Hepatic:
• •Bilirubin no greater than 2 mg/dL (unless secondary to tumor)
• •AST or ALT less than 3 times upper limit of normal
• •Hepatitis B surface antigen negative
• •Hepatitis C RNA negative
• •Renal:
• •Creatinine no greater than 2.0 mg/dL
• •Cardiovascular:
• •Left ventricular ejection fraction at least 45% by echocardiogram or MUGA
• •Pulmonary:
• •DLCO, FEV\_1, and FVC greater than 50% of predicted
• •Other:
• •No active infection requiring oral or IV antibiotics
• •No other prior malignancy within the past two years except basal cell skin cancer or carcinoma in situ of the cervix
• •HIV negative
• •Not pregnant or nursing
• •Negative pregnancy test
• •Fertile patients must use effective contraception
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy:
• •Prior monoclonal antibody CD52 allowed if at least partial remission was achieved with last treatment
• •Chemotherapy:
• •No more than 2 prior chemotherapy regimens
• •At least 3 weeks since prior chemotherapy
• •No more than 8 courses of prior fludarabine therapy
• •Endocrine therapy:
• •Not specified
• •Radiotherapy:
• •Not specified
• •Surgery:
• •Not specified